Consilium MedicumConsilium MedicumConsilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum92547ArticlesСтатьиResearch ArticleAntiaritmicheskiy effekt statinov pri zheludochkovykh narusheniyakh ritma vysokoy gradatsii i mertsatel'noy aritmiiАнтиаритмический эффект статинов при желудочковых нарушениях ритма высокой градации и мерцательной аритмииAronovD. MАроновД. МФГУ Государственный научно-исследовательский центр профилактической медицины Росздрава, Москва15112007911VOL 9, NO11 (2007)ТОМ 9, №11 (2007)909628122021Copyright ©; 2007, Consilium MedicumCopyright ©; 2007, ООО "Консилиум Медикум"2007Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://consilium.orscience.ru/2075-1753/article/view/92547

Основное назначение статинов – антиатеросклеротическое действие после продолжительного (не менее 3–5 лет) лечения. В данном случае речь идет о первоначальном предназначении статинов – блокировать синтез холестерина на уровне ГМККоА-редуктазы, что приводит к развитию гипохолестеринемии и далее – к антиатеросклеротическому эффекту. Но фактически оказалось, что статины кроме гиполипидемического и, следовательно, антиатеросклеротического эффекта обладают самыми разнообразными терапевтическими свойствами, которые позволяют им влиять не только на нарушенные функции сердечно-сосудистой системы, но и различных других органов и систем, не имеющих отношения к обмену липидов и атеросклерозу. Эти дополнительные (плейотропные) нелипидные свойства статинов систематизированы в таблице. Как видно, среди этих свойств числится и такое свойство статинов, как антиаритмическое. Впервые антиаритмическое свойство статинов было показано в исследовании J. De Sutter и соавт. (2000 г.).

аритмиянарушения ритма сердцастатиныАронов Д.М. Лечение и профилактика атеросклероза. М.: Триада-Х, 2000.Аронов Д.М. Каскад терапевтических эффектов статинов. Кардиология. 2004; 85–94.Bayes de Luna A, Coumel P, Leclereq J.F. Ambu latory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J 1989; 117: 151–9.Chen J, Shen H, Nagasawa Y et al. Pravastatin Inhibits Arrhithmias Induced by Coronary Artery Ischemia in Anesthetized Rats. J Pharmacol Sci 2007; 103(3): 317–22.Chiu J.H, Abdelhadi R.H et al. Effect of statin therapy on risk of ventricular arrhythmia among patients with coronary artery disease and an implantable cardioverter - defibrillator. Am J Cardiol 2005; 95: 490–1.Crespo E.M, Kim J, Selzman K.A. The use of implantable cardioverter defibrillators for the prevention of sudden cardiac death: a review of the evidence and implications. Am J Med Sci 2005; 329(5): 238–46.De Sutter J, Kazmierczak J, Fonteyne W et al. Factors determining long - term outcomes and survival in patients with coronary artery disease and ventricular tachyarrhythmias: a single cen ter experience. Pacing Clin Electrophysiol 2000; 23(11 Pt 2): 1947–52.Dickinson M.G, Ip J.H et al. Statin use was asso ciated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: Mortali ty data and mechanistic insights from the Sud den Cardiac Death in Heart Failure Trial (SCD-HeFT). Am Heart J 2007; 153: 573–8.Hanna I.R, Heeke B, Bush H et al. Lipid - lower ing drug use is associated with reduced preva lence of atrial fibrillation in patients with left ventricular systolic dysfunction. Heart Rhythm 2006; 3(8): 881–6.Horne B.D, Muhlestein J.B, Carlquist J.F et al. Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographi cally severe coronary artery disease. J Am Coll Cardiol 2000; 36(6): 1774–80.Goldberger J, Subacius H, Schaechter R.N et al. Effects of Statin Therapy on Arrhythmic Events and Survival in Patients With Nonischemic Dilated Cardiomyopathy. JACC 2006; 48(6): 1228–33.Kumagai K, Nakashima H, Saku K. The HMG-CoA reductase inhibitor atorvastatin pre vents atrial fibrillation by inhibition in a canine sterile pericarditis model. Cardiovasc Research 2004; 62: 105–11.Kwok K.M, Lee K.L.F et al. Sudden cardiac death: prevention and treatment. Hong Kong Med J 2003; 9: 357–62.Lorenz H, Junger C, Seidl K et al. Do statin influence the prognostic impact of non - sustained ventricular tachycardia after ST-eleva tion myocardial infarction? Eur Heart J 2005; 26: 1078–85.Mitchell L.B, Powell J.L et al. Are lipid - lowering drugs? An analysis of the antiarrhythmics versus implantable defibrillators (AVID) trial. J Am Coll Cardiol 2003; 42: 81–7.Moss A.J. Should everyone with an ejection fraction less than or equal to 30% receive an implantable cardioverter - defibrillator? Every one with an ejection fraction < or = 30% should receive an implantable cardioverter - defibrilla tor. Circulation 2005; 111(19): 2537–49.Оkazaki S, Yokoyama T et al. Early statin treatment in patients with acute coronary syn drome demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event the ESTABLISH Study. Circulation 2004; 110(9): 1061–8.Ozaydin M, Kapan S, Tuzun N et al. Statin use before by - pass surgery decreases the incidence and shortens the duration of postoperative atrial fibrillation. Cardiology 2007; 107(2): 117–21.Pasceri V, Patti G, Nusca A et al. Randomized Trial of Atorvastatin for Reduction of Myocardial Damage During Coronary Intervention. Circula tion 2004; 110: 674–78.Patti G, Chello M, Candura D et al. Random ized Trial of Atorvastatin for Reduction of Post operative Atrial Fibrillation in Patients Undergo ing Cardiac Surgery. Circulation 2006; 114: 1455–61.Pehlivanidis A.N, Athyros V.G, Demitriadis D.S et al. Heart rate variability after long - term treat ment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease. Atherosclerosis 2001; 157(2): 463–9.Pliquett R.U, Cornish K.G, Zucker I.H. Statin therapy restores sympathovagal balance in experimental heart failure. J Appl Physiol 2003; 95(2): 700–4.Pliquett R.U, Cornish K.G et al. Simvastatin normalizes autonomic neural control in experi mental heart failure. Circulation 2003; 107(19): 2493–8.Priori S.G, Allot E, Blondstrom-Lundqvist C et al. Task Force on Sudden Cardiac Death of the ESC. Eur Heart 2001; 22: 16.Rikitake Y, Kawashima S et al. Anti - oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atheroscle rosis in cholesterolfed rabbits. Atherosclerosis 2001; 154(1): 87–96.Schwartz G.G, Olsson A.G, Ezekowitz M.D et al. Effect of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRA CL study: randomized controlled trial. JAMA; 2001; 285: 1711–8.Shiroshita-Takeshita A, Schram G, Lavoie J, Nattei S. Effect of simvaststin and antioxidant vitamins on atrial fibrillation promotion by atri al - tachycardia remodeling in dogs. Circulation 2004; 110(16): 2313–9.Tang Q, Huang J, Qian H, Chen L et al. Antiarrhythmic effect of atorvastatin on autoim mune myocarditis is mediated by improving myocardial repolarization. Life Sci 2007; 80(7): 601–8.van Nienw Amerongen G.P, Vermeer M.A et al. Simvastatin improves disturbed endotelial bar rier function. Circulation 2000; 102: 2803–9.Vias K.V, Guo H, Moss A.J et al. Reduction in Ventricular Tachyarrhythmias With Statins in the Multicenter Automatic Defibrillator Implanta tion Trial (MADIT)–II. J Am Coll Cardiol 2006; 47(4): 769–73.Vrtovec B, Okrajsek R et al. Atorvastatin ther apy increases heart rate variability, decreases QT variability, and shortens QT c interval dura tion in patients with advanced chronic heart failure. J Card Fail 2005; 11(9): 691–2.Young-Xu Y, Jabbour S et al. Usefulness of statin drugs in protecting against atrial fibrilla tion in patients with coronary artery disease. Am J Cardiol 2003; 92(12): 1379–83.